Idera Pharmaceuticals (Nasdaq: IDRA) today announced that Nicola La
Monica, Ph.D., Vice President of Biology at Idera, will present at the
Cancer Immunotherapy Summit on February 28, 2012, at 2:30 pm ET in
Boston, MA. Dr. La Monica, in an oral presentation entitled “TLR
Modulation for Immunotherapy of Cancer”, will provide an overview of
Idera’s oncology program using agonists of Toll-like receptors (TLRs).
Idera’s TLR agonist candidates modulate receptor-mediated immune
responses and are being studied as immune modifiers in the potential
therapy of cancer.
Idera has developed a portfolio of TLR agonists for the treatment of
various cancer indications both in combination with targeted agents as
well as for use as vaccine adjuvants. Idera’s portfolio includes:
IMO-2055, a TLR9 agonist – Idera recently announced positive from a
Phase 1b results of IMO-2055 in combination with Tarceva® and Avastin®
in patients with advanced non-small cell lung cancer. Results from a
Phase 2 study of IMO-2055 in combination with Erbitux® for the
treatment of squamous cell cancer of the head and neck are expected in
the second quarter of 2012
TLR 7,8 and 9 agonists – Idera recently announced that Merck has
selected several novel TLR agonists targeted to TLR7, TLR8 or TLR9 for
evaluation and use as vaccine adjuvant candidates under the companies'
collaboration and license agreement
IMO-4200 – Idera-4200 is a dual agonist of TLR7 and 8. Idera has
conducted preclinical studies of IMO-4200 for hematological
TLR3 agonists – Idera has identified novel TLR3 agonists for potential
use as adjuvants in combination with cancer vaccines
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals applies its proprietary Toll-like Receptor (TLR)
drug discovery platform to create immunomodulatory drug candidates. The
Company's TLR-targeted candidates are being developed to treat
autoimmune and inflammatory diseases and cancer, and for use as vaccine
adjuvants. Additionally, the Company is advancing its gene-silencing
oligonucleotide (GSO) technology for the purpose of inhibiting the
expression of disease-promoting genes. For more information, visit http://www.iderapharma.com.
Idera Forward Looking Statements
This press release contains forward-looking statements concerning Idera
Pharmaceuticals, Inc. that involve a number of risks and uncertainties.
For this purpose, any statements contained herein that are not
statements of historical fact may be deemed to be forward-looking
statements. Without limiting the foregoing, the words "believes,"
"anticipates," "plans," "expects," "estimates," "intends," "should,"
"could," "will," "may," and similar expressions are intended to identify
forward-looking statements. There are a number of important factors that
could cause Idera's actual results to differ materially from those
indicated by such forward-looking statements, including whether early
clinical results such as the results described in this release will be
indicative of results obtained in later clinical trials; whether
products based on Idera's technology will advance into or through the
clinical trial process on a timely basis or at all and receive approval
from the United States Food and Drug Administration or equivalent
foreign regulatory agencies; whether, if the Company's products receive
approval, they will be successfully distributed and marketed; whether
the Company's collaborations will be successful; whether Idera's cash
resources will be sufficient to fund the Company's operations; and such
other important factors as are set forth under the caption "Risk
Factors" in Idera's Quarterly Report on Form 10-Q for the quarter ended
September 30, 2011 which important factors are incorporated herein by
reference. Idera disclaims any intention or obligation to update any
IMO(R) and Idera(R) are our trademarks. All other trademarks and service
marks appearing in this release are the property of their respective